Company / Operating Cash Flow
CytomX Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$75.6M
FY2025
5-year range
-$119.0M / -$56.0M
FY2021-FY2025
Trend
+12.3%
vs FY2024
Sector context
#112 of 216
Health Care
What the data says
At -$76M, CytomX Therapeutics, Inc.'s operating cash flow ranks #112 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$140M in FY2019 to $170M in FY2017.
Based on SEC 10-K filings.
-$76M in FY2025.
Declined from -$56M to -$76M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#112 of 216 in Health CareTop 52% of 216This company -$75.6M Sector average $658.7M
▼
-111.5% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 12.3% year-over-year.
- Ranks #112 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$75.6M | +12.3% |
| FY2024 | -$86.2M | -53.9% |
| FY2023 | -$56.0M | +49.4% |
| FY2022 | -$110.8M | +6.9% |
| FY2021 | -$119.0M | -2363.4% |
| FY2020 | $5.3M | +103.7% |
| FY2019 | -$140.5M | -86.0% |
| FY2018 | -$75.5M | -144.3% |
| FY2017 | $170.4M | +8484.5% |
| FY2016 | -$2.0M | +74.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026